* respiratory rate \>24/min * pregnancy (tested with a pregnancy test) or lactation * weight \<50 kg * hemodynamic/rhythm instability * acute myocardial infarction type 1 * use of concomitant medications that prolong the qt/qtc interval. * any regular concomitant medication which is contraindicated in the use together with hcq * hypersensitivity to hydroxychloroquine, chloroquine or other 4-aminoquinolines * pre-existing retinopathy or maculopathy * known glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, favism) * haematopoietic systems diseases * myasthenia gravis * any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data additionally, clinical evaluation and laboratory values inform eligibility of the patient based on the judgement of the study team. these may include: total bilirubin, transaminase level, albumin concentration, haematological parameters, troponin and bnp levels, creatinine, creatinine kinase levels.

* respiratory rate \>24/min * pregnancy (tested with a pregnancy test) or lactation * weight \<50 kg * hemodynamic/rhythm instability * acute myocardial infarction type 1 * use of concomitant medications that prolong the qt/qtc interval. * any regular concomitant medication which is contraindicated in the use together with hcq * hypersensitivity to hydroxychloroquine, chloroquine or other 4-aminoquinolines * pre-existing retinopathy or maculopathy * known glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, favism) * haematopoietic systems diseases * myasthenia gravis * any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data additionally, clinical evaluation and laboratory values inform eligibility of the patient based on the judgement of the study team. these may include: total bilirubin, transaminase level, albumin concentration, haematological parameters, troponin and bnp levels, creatinine, creatinine kinase levels.

- respiratory rate >24/min - pregnancy (tested with a pregnancy test) or lactation - weight <50 kg - hemodynamic/rhythm instability - acute myocardial infarction type 1 - use of concomitant medications that prolong the qt/qtc interval. - any regular concomitant medication which is contraindicated in the use together with hcq - hypersensitivity to hydroxychloroquine, chloroquine or other 4-aminoquinolines - pre-existing retinopathy or maculopathy - known glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, favism) - haematopoietic systems diseases - myasthenia gravis - any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data additionally, clinical evaluation and laboratory values inform eligibility of the patient based on the judgement of the study team. these may include: total bilirubin, transaminase level, albumin concentration, haematological parameters, troponin and bnp levels, creatinine, creatinine kinase levels.

- respiratory rate >24/min - pregnancy (tested with a pregnancy test) or lactation - weight <50 kg - hemodynamic/rhythm instability - acute myocardial infarction type 1 - use of concomitant medications that prolong the qt/qtc interval. - any regular concomitant medication which is contraindicated in the use together with hcq - hypersensitivity to hydroxychloroquine, chloroquine or other 4-aminoquinolines - pre-existing retinopathy or maculopathy - known glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, favism) - haematopoietic systems diseases - myasthenia gravis - any other significant disease, disorder or finding which, in the opinion of the investigator, may significantly increase the risk to the volunteer because of participation in the study, affect the ability of the volunteer to participate in the study or impair interpretation of the study data additionally, clinical evaluation and laboratory values inform eligibility of the patient based on the judgement of the study team. these may include: total bilirubin, transaminase level, albumin concentration, haematological parameters, troponin and bnp levels, creatinine, creatinine kinase levels.